An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation.

"Competing Interests The authors declare no relevant conflicts of interest. The study depicted here has been filed for a US provisional patent application 61/953,458 (inventors Robert Hancock, Olga Pena, David Hancock and John Boyd) which claims the use of the signature for diagnosing sepsis and the use of molecules that reverse the endotoxin tolerant state of immune cells as a therapeutic strategy."

"We would like to acknowledge the Canadian Institutes of Health Research (MOP-74493 and MCT-44152) for funding this study. We thank Reza Falsafi and Mihai Cirstea for the excellent technical support in the processing of samples. OP held a Vanier-CIHR Doctoral Scholarship, NHL an AMMI/Pfizer Post Residency and UBC Clinician Investigator fellowship, JX a CIHR and UBC Killam postdoctoral fellowship, CDJ a CIHR postdoctoral fellowship, and REWH a Canada Research Chair. Role of the Funding Source The funding source, Canadian Institutes of Health Research (MOP-74493 and MCT-44152), provided support for this research but was not involved in any aspect pertinent to the study."